0001572426-15-000078.txt : 20150714 0001572426-15-000078.hdr.sgml : 20150714 20150714183051 ACCESSION NUMBER: 0001572426-15-000078 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150713 FILED AS OF DATE: 20150714 DATE AS OF CHANGE: 20150714 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nexvet Biopharma plc CENTRAL INDEX KEY: 0001618561 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: NATL INST FOR BIOPROCESSING RESEARCH STREET 2: FOSTERS AVENUE, MOUNT MERRION CITY: BLACKROCK CO. DUBLIN STATE: L2 ZIP: 00000 BUSINESS PHONE: 353 1 215 8100 MAIL ADDRESS: STREET 1: NATL INST FOR BIOPROCESSING RESEARCH STREET 2: FOSTERS AVENUE, MOUNT MERRION CITY: BLACKROCK CO. DUBLIN STATE: L2 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: NEXVET BIOPHARMA Ltd DATE OF NAME CHANGE: 20140903 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gunn George W CENTRAL INDEX KEY: 0001639458 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36828 FILM NUMBER: 15988085 MAIL ADDRESS: STREET 1: C/O NEXVET BIOPHARMA PLC STREET 2: NIBRT, FOSTERS AVENUE, MOUNT MERRION CITY: BLACKROCK STATE: L2 ZIP: 0000 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2015-07-13 0001618561 Nexvet Biopharma plc NVET 0001639458 Gunn George W C/O NEXVET BIOPHARMA PLC NIBRT; FOSTERS AVENUE, MOUNT MERRION BLACROCK L2 IRELAND 1 0 0 0 Ordinary Shares 2015-07-13 4 M 0 900 .125 A 900 D Ordinary Shares 2015-07-13 4 M 0 500 .125 A 1400 D Restricted Share Units .125 2015-07-13 4 M 0 900 0 D 2015-06-30 2019-07-01 Ordinary Shares 900 0 D Restricted Share Units .125 2015-07-13 4 M 0 500 0 D 2015-06-30 2019-07-01 Ordinary Shares 500 5500 D 500 of the Restricted Share Units vested and became convertible on 6/30/15, and shall vest and become convertible with respect to an additional 500 shares on each of 9/30/15, 12/31/15, 3/31/16, 6/30/16, 9/30/16, 12/31/16, 3/31/17, 6/30/17, 9/30/17, 12/31/17 and 3/31/18 in each case subject to payment of the nominal value per share to Issuer within 30 days of vesting. /s/ George W. Gunn by Geraldine Farrell, Attorney-in-Fact 2015-07-13